Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phathom Pharmaceuticals

4.03
-0.1950-4.62%
Post-market: 4.030.00000.00%19:40 EDT
Volume:956.15K
Turnover:3.94M
Market Cap:275.56M
PE:-0.76
High:4.30
Open:4.30
Low:4.02
Close:4.23
Loading ...

Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
18 Apr

Press Release: Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

Dow Jones
·
16 Apr

Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
09 Apr

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?

Zacks
·
08 Apr

Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders

Simply Wall St.
·
07 Apr

Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
02 Apr

BRIEF-Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
02 Apr

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 Apr

Phathom Pharmaceuticals Stock Falls on CEO Switch

Dow Jones
·
02 Apr

Phathom Pharmaceuticals Names Basta President, CEO as Curran Resigns

Dow Jones
·
01 Apr

Phathom Pharmaceuticals Names Steven Basta CEO

MT Newswires Live
·
01 Apr

Phathom Pharmaceuticals appoints Basta as President, CEO

TIPRANKS
·
01 Apr

BRIEF-Phathom Pharmaceuticals Announces Leadership Succession

Reuters
·
01 Apr

Phathom Pharmaceuticals Announces Leadership Succession

THOMSON REUTERS
·
01 Apr

Phathom Pharmaceuticals Inc - Terrie Curran Steps Down as President and CEO of Phathom Pharmaceuticals

THOMSON REUTERS
·
01 Apr

Press Release: Phathom Pharmaceuticals Announces Leadership Succession

Dow Jones
·
01 Apr

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

GlobeNewswire
·
31 Mar

Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating

MT Newswires Live
·
20 Mar

Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges

TIPRANKS
·
11 Mar

Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
11 Mar